Cognitive Health AI

What Cognitive Health AI does

Cognitive Health AI (DBA Omina) is a Delaware C-Corp founded in 2024 and headquartered in Plano, Texas, building a clinical-grade AI platform for chronic skin conditions. The company focuses on psoriasis and NF1 (cutaneous neurofibromas), where it claims 40% of biologic patients fail their first treatment, costing $50K+ per patient in wasted spend, with an average 3-month gap between clinical visits and no objective monitoring. Its core product, Omina, runs a multi-modal AI pipeline combining a Vision Transformer for skin photo analysis, an NLP Engine for symptom reports, a knowledge graph spanning 50,000+ dermatology citations for Retrieval-Augmented Generation (RAG) of cited clinical evidence, and "Horizon Models" (LSTM + Transformer time-series models) that forecast flare windows approximately two weeks ahead once 12+ weeks of patient data are collected. Validation includes a stated 95% accuracy against dermatologist PASI scoring on 26,000+ annotated images, with a Massachusetts General Hospital clinical pilot and an FDA Class II submission planned for Q1 2027.

The platform is offered in three tiers: Omina Pro at $29/month for individual patients (unlimited AI skin assessments and condition monitoring), Omina Clinic at $499/month for practices (up to 150 patient profiles and 5 provider accounts), and Omina Enterprise at custom pricing for pharma and health systems (real-world evidence licensing, population analytics, custom API integration, dedicated success manager, and white-label options). Distribution is hybrid: a self-serve patient funnel via a pre-launch waitlist, inside sales to dermatology practices, and enterprise field sales to pharma and health systems. The company is in pre-launch development and has not disclosed revenue or institutional funding rounds. Technology dependencies include Google Firebase (BAA effective March 9, 2026) for authentication, data, and photo storage, and Anthropic's Claude API for AI analysis output generation under commercial terms without a BAA, with data typically deleted within approximately seven days.

Leadership consists of two co-founders: Aravind Pranav Thirunagari (Founder & CEO; MS Computer Science, UT; Vector AI Institute '24) and Sreevatsav Shod (Co-Founder & CTO; engineering background, full-stack and mobile). Strategic partners and recognition include Massachusetts General Hospital (clinical pilot), Children's Tumor Foundation (NF1 partner), NVIDIA Inception (Edge AI development), GSK (Top 10 AI Healthcare 2024), Vector AI Institute (2024 healthcare cohort), Google Firebase, Anthropic, and Oracle NetSuite. The company's planned milestones are a 2026 platform launch with a 1,000-user target and an FDA Class II submission in Q1 2027; until cleared, the product is explicitly labeled "Not a medical device / Not FDA-cleared / Informational use only."

Name

Cognitive Health AI

Legal name

Cognitiv Health Inc.

Website

https://cognitivhealth.co

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Cognitive Health AI (Omina) builds a clinical-grade AI platform that provides longitudinal tracking, evidence-cited analysis, and two-week flare forecasting for psoriasis and NF1 chronic skin conditions, serving individual patients, dermatology practices, and pharma/health systems via Pro, Clinic, and Enterprise SaaS tiers.

Ownership category

akta.pro rank

Headquarters

HQ city

Denton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Patient Subscription (Pro): Monthly subscription at $29/mo for individual patients. Includes unlimited AI skin assessments, treatment response tracking, progress analytics, NF1 tumor count tracking, and psoriasis & eczema monitoring.
2. Clinic Subscription: Monthly subscription at $499/mo for practices. Includes up to 150 patient profiles, 5 provider accounts, clinic dashboard & reporting, HIPAA compliance, and email & chat support.
3. Enterprise Licensing: Custom pricing for pharma & health systems including real-world evidence licensing, population-level analytics, custom API integration, dedicated success manager, HIPAA BAA included, and white-label options.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Omina is a clinical-grade AI platform for chronic skin conditions (Psoriasis and NF1/Cutaneous Neurofibromas) that combines skin photo analysis, longitudinal patient data, and clinical evidence retrieval to deliver treatment response tracking and 2-week flare forecasting. The platform is sold via subscriptions: Omina Pro for individual patients at $29/month, Omina Clinic for dermatology practices at $499/month, and Omina Enterprise for pharma and health systems with custom pricing, real-world evidence licensing, and white-label options.

Product overview

Omina is a unified clinical-grade AI platform for chronic skin conditions (Psoriasis and NF1/Cutaneous Neurofibromas) with three product tiers: Omina Pro (patient-facing, $29/month) for individual monitoring and treatment tracking; Omina Clinic (clinic-facing, $499/month) for practices managing up to 150 patients with provider accounts and reporting; and Omina Enterprise (pharma/health system-facing, custom pricing) for real-world evidence and population analytics. The platform's core technology comprises Vision Transformer for skin photo analysis, RAG Technology for cited evidence retrieval from 50,000+ dermatology citations, and Horizon Models (LSTM + Transformer) for flare forecasting. Currently in pre-launch with platform launch planned for 2026 and FDA Class II submission planned for Q1 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• Omina Clinical-grade AI platform for chronic skin conditions (Psoriasis and NF1/Cutaneous Neurofibromas) providing longitudinal tracking, AI-assisted skin photo analysis, and flare forecasting via a three-step Capture & Track → Analyze → Forecast protocol. Sold via three subscription tiers: Omina Pro for patients ($29/month), Omina Clinic for practices ($499/month), and Omina Enterprise for pharma and health systems (custom pricing with real-world evidence licensing and white-label options).

Quantifiable outcome

• 40% of biologic patients fail first treatment - company addresses this with objective tracking
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Massachusetts General HospitalcoreStrategic or Co-development Partner · 1 January 2025Clinical pilot partner conducting research collaboration. MGH partnership for clinical validation and FDA Class II planned submission in Q1 2027.
• NVIDIA InceptionminorStrategic or Co-development PartnerAccepted into NVIDIA Inception program providing technical resources, mentorship, and GPU cloud credits for AI development.
• Vector AI InstituteminorStrategic or Co-development PartnerHealthcare AI cohort participant. Founder Aravind Pranav Thirunagari completed Vector AI Institute '24 program.
• Children's Tumor FoundationcoreStrategic or Co-development PartnerCTF Partner Company with Edge AI development focus for NF1 (neurofibromatosis) patient monitoring.
• GSKminorStrategic or Co-development PartnerGSK Top 10 AI Healthcare 2024 recognition. Company founded to address biologic treatment failure problem relevant to GSK's drug portfolio.
• Google FirebasecoreTechnology or IntegrationFirebase for account authentication, Firestore database, and Cloud Storage for photos. Signed BAA effective March 9, 2026 covering HIPAA compliance.
• AnthropiccoreTechnology or IntegrationClaude API for AI analysis processing. Photos sent to Anthropic for tracking output generation. Processing governed by commercial API terms; data typically deleted within ~7 days.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• VisualDx: Clinical decision support platform with a large dermatology image library and AI-assisted differential diagnosis used by clinicians. Most directly comparable to Omina on the clinician-facing evidence-backed AI layer; competes for the same dermatology practice budget.
• SkinVision: Consumer and clinician dermatology AI app focused on skin cancer risk and lesion tracking via smartphone photos. Direct peer on the AI image analysis layer, though SkinVision's primary focus is melanoma risk rather than chronic inflammatory conditions like psoriasis and NF1.
• Miiskin: Consumer skin tracking app for monitoring moles, psoriasis, and eczema with photo-based longitudinal tracking. Closely overlaps Omina's Pro tier feature set (unlimited AI skin assessments, treatment tracking) and target persona of chronic skin condition patients.
• Skin Analytics: UK-based dermatology AI company with Class II CE-marked and FDA pathway product for skin cancer detection, deployed in NHS pathways. Direct regulatory and clinical-validation peer, though focused on dermatology-oncology rather than chronic inflammatory disease.
• MetaOptima: Developer of MoleScope and DermEngine—AI dermoscopy and teledermatology platforms used by clinics for skin imaging and lesion tracking. Direct peer on the clinic SaaS tier with image-based AI and longitudinal patient records.

Broad incumbents

• Google DermAssist: Google's dermatology AI assistant launched in 2021 that analyzes skin photos using computer vision. As a Big Tech incumbent with massive distribution through Google Search and Pixel, DermAssist represents the most significant distribution threat to consumer-tier dermatology AI.
• Hims & Hers Health: Public telehealth company with significant dermatology franchise including prescription skincare and chronic skin condition treatment. Broad incumbent that could integrate AI skin tracking as a feature into an existing 2M+ subscriber base, posing distribution risk to Omina Pro.
• Teladoc Health: Large telemedicine platform with dermatology service line and growing virtual care footprint. Broad incumbent that could integrate AI dermatology image analysis into its enterprise health system contracts, competing for the same pharma/health-system enterprise RWE tier.

Emerging players

• DermaSensor: FDA-cleared (2024) handheld device using AI to evaluate skin lesions for cancer risk at point of care. Emerging regulatory and clinical peer; demonstrates a viable FDA Class II pathway for dermatology AI but operates in oncology rather than chronic inflammatory disease.
• First Derm: AI-powered teledermatology platform that triages skin concerns via photo upload with dermatologist review. Emerging peer with overlapping patient-facing AI skin assessment and remote dermatology workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cognitive Health AI